Early Pharmacovigilance Reports for Apitegromab in Spinal Muscular Atrophy Using VigiAccess Data
This study presents a preliminary analysis of eight publicly available pharmacovigilance reports for apitegromab in spinal muscular atrophy from the VigiAccess database, highlighting sparse data that includes pre-approval cases and underscores the inability to establish definitive safety profiles or causality at this early stage.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
When a new medicine is developed to treat a serious condition, the journey does not end when regulators give it the green light. Instead, a crucial second phase begins: watching how the drug behaves in the real world, outside the controlled environment of clinical trials. This ongoing watchfulness, known as pharmacovigilance, relies on collecting reports of any health problems that occur after a patient starts taking a medication. These reports help doctors and scientists spot patterns that might have been missed during initial testing. One such new treatment is apitegromab, a therapy designed to help people with spinal muscular atrophy, a genetic disorder that weakens muscles. Unlike previous treatments that focus on the genetic instructions inside cells, this new drug works directly on the muscles themselves, aiming to stop them from wasting away. Because this approach is relatively new for this specific disease, understanding what happens when the drug is used by thousands of patients is vital for ensuring long-term safety.
A recent report by researchers at the University of Karachi offers a first, very early look at the safety data for apitegromab. The team examined a public database maintained by the World Health Organization, which gathers health reports from around the globe. They searched for any entries linked to apitegromab as of mid-September 2026, just days after the drug received official approval in the United States. The goal was not to prove that the drug causes specific problems, but simply to see what information was already available in the public record at that precise moment. The search yielded a very small number of entries: only eight reports in total. This scarcity is expected, as the drug had only just become available to the public, and it takes time for reports to be filed and entered into the system.
The eight reports described patients ranging in age from two to seventeen years old, with entries coming from both the Americas and Europe. The health issues listed in these reports were varied. The most frequent category involved problems with muscles, bones, and connective tissue, specifically mentioning scoliosis, which is a curvature of the spine. Other reports listed injuries or complications from medical procedures, such as pain following a procedure or issues related to spinal taps. There were also isolated mentions of heart rhythm changes, stomach upset, infections like pneumonia, and various other conditions affecting the blood, nerves, and skin. Because a single report can list multiple different health issues, the total number of specific symptoms mentioned is higher than the number of reports themselves.
Despite the presence of these reports, the researchers are very clear about what this data cannot tell us. The database only shows that a report was made; it does not provide the full medical story behind it. It is impossible to know from these aggregate numbers whether the drug caused the symptoms, whether the symptoms were due to the underlying spinal muscular atrophy, or if they resulted from other treatments the patients were receiving. Furthermore, because the database does not track how many people have taken the drug, it is impossible to calculate how often these problems occur. The researchers explicitly state that these eight reports do not prove the drug is unsafe, nor do they confirm that the drug is safe. They are simply a starting point, a collection of initial signals that need much more data to be understood.
The report also highlights a curious detail in the timeline: some of the health issues were recorded in 2021 and 2022, years before the drug was officially approved. This suggests that some of the data may have come from clinical trials or special access programs rather than general public use. The researchers caution that without knowing the exact source of each report, it is premature to call this an established safety profile. The findings do not contradict the known risks listed in the official drug information, nor do they confirm them. Instead, they serve as a reminder that safety monitoring is a continuous process. As more people begin to use apitegromab in everyday medical practice, more reports will be filed, and only then will scientists be able to distinguish between rare side effects and the natural course of the disease. For now, the data remains sparse, and the primary conclusion is that continued observation is necessary as real-world use expands.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.